Myriad Genetics (MYGN) Net Cash Flow (2016 - 2026)
Myriad Genetics has reported Net Cash Flow over the past 17 years, most recently at -$3.6 million for Q4 2025.
- Quarterly Net Cash Flow fell 228.57% to -$3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38.6 million through Dec 2025, up 237.86% year-over-year, with the annual reading at $38.6 million for FY2025, 237.86% up from the prior year.
- Net Cash Flow was -$3.6 million for Q4 2025 at Myriad Genetics, down from $71.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $177.2 million in Q3 2021 and troughed at -$92.6 million in Q1 2022.
- The 5-year median for Net Cash Flow is -$3.6 million (2023), against an average of $1.8 million.
- The largest YoY upside for Net Cash Flow was 1294.12% in 2025 against a maximum downside of 1178.57% in 2025.
- A 5-year view of Net Cash Flow shows it stood at -$36.5 million in 2021, then decreased by 23.29% to -$45.0 million in 2022, then skyrocketed by 222.67% to $55.2 million in 2023, then tumbled by 94.93% to $2.8 million in 2024, then crashed by 228.57% to -$3.6 million in 2025.
- Per Business Quant, the three most recent readings for MYGN's Net Cash Flow are -$3.6 million (Q4 2025), $71.1 million (Q3 2025), and -$17.9 million (Q2 2025).